Skip to Content

X4 Pharmaceuticals Inc

Rating as of

Company Profile

Business Description

X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme.

955 Massachusetts Avenue, 4th Floor
Cambridge, MA, 02139
T +1 857 529-8300
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 58